Novavax Begins Phase III Study on Influenza Vaccine Candidate

Novavax, Inc. NVAX announced that it has initiated a phase III study on its nanoparticle seasonal influenza vaccine candidate NanoFlu. The pivotal study will evaluate the safety and immunogenicity of NanoFlu using the company’s proprietary Matrix-M adjuvant in adult patients aged 65 years and above compared to the quadrivalent influenza vaccine licensed in the United States.